OPEN ACCESS Freely available online

ISSN: 2153-2435
Pharmaceutica Analytica Acta

Perspective

UV Visible Spectroscopy and Drug Stability of Pharmaceutical Analysis

Chew Lim*

Department of Materials Science, Tongji University, Shanghai, China

DESCRIPTION

Visible light, X-rays, and ultraviolet radiation are all the parts of the electromagnetic spectrum UV light has a spectrum of wavelengths between 10 and 400 manometers. The wavelength of violet light is approximately 400 manometers (4,000). Around 800 terahertz (THz, or 1012 hertz), or the range of 30,000 THz, is where ultraviolet radiation oscillates. Particles with thermal energy are moving at nearly constant speeds. The particles are accelerating electromagnetic radiation is created by charged particles accelerating. The acceleration squared determines the amount of power released. Faster frequency (shorter wavelength) radiation is produced by higher rates of velocity change. The near UV region, which has wavelengths between 200 and 400 nm, is the closest to visible light The higher energy, shorter wavelength far UV region spans wavelengths between 91 and 200 nm. Extreme UV radiation, which is on the borderline of UV and X-ray radiation, has the shortest wavelength range and highest energy of the regions of the ultraviolet spectrum.

Stability testing is an essential part of the drug approval process, but it also plays a crucial role in helping pharmaceutical companies in identifying the drugs are most likely to be commercially viable. The process of creating new pharmaceuticals is exciting since it creates possibilities for preserving health and improving quality of life. Pharmaceutical development is an exacting, time-consuming, and labour-intensive process because of the high risks involved as new medications must be subjected to rigorous testing to determine efficacy and ensure that drugs conform to strict performance standards prior to release. When evaluating drug stability indicators at all stages of drug development and manufacturing, UV-Vis spectrophotometry provides a quick, affordable, and accurate method. This technology provides pharmaceutical companies with the vital information they need to predict product viability. An appealing tool for the investigation, diagnosis, prognosis, and therapy of many cancers is a measure of tissue characteristics that is physically or physiologically significant. The field of tissue optical spectroscopy has recently made significant strides due to the improvement of methodologies to translate measured reflectance and fluorescence spectra from tissue to cancer-relevant parameters vascular volume, oxygenation, the amount of extracellular matrix, metabolic redox states, and cellular proliferation are a few examples.

The ability to determine the proper shelf-life, storage, and usage guidelines for end users is provided by drug stability testing to pharmaceutical companies. However, drug stability testing also helps users predict which drugs will be commercially viable early on in the development process, make informed decisions regarding resource allocation. Researchers can objectively evaluate a number of important stability indicators, including the determination of Active Pharmaceutical Ingredients (API) and the detection of impurities, using UV-Vis spectrophotometry, which quantifies the quantity of UV or visible light absorbed by a substance. The analytical abilities of spectrophotometry make it useful for quality control during manufacturing and excellent for various types of stability testing. Even though a medicine may be perfectly designed and stable when it is being produced, environmental stressors such light, temperature, pH fluctuations, oxidation, and hydrolysis can lead to chemical changes that destabilize the chemical structure of the medication. Most of the medications are made up of tiny chemical compounds.

Correspondence to: Chew Lim. Department of Materials Science, Tongji University, Shanghai, China, E-mail: chew.lu.ck.lim@gmail.com

Received: 01-Jul-2022, Manuscript no: PAA-22-17425, **Editorial assigned**: 05-Jul-2022, PreQC no: PAA-22-17425 (PQ), **Reviewed**: 20-Jul-2022, QC no: PAA-22-17425, **Revised**: 28-Jul-2022, Manuscript no: PAA-22-1 7425 (R), **Published:** 05-Aug-2022, DOI: 10.35248/2153-2435.22.13.680

Citation: Lim C (2022) UV Visible Spectroscopy and Drug Stability of Pharmaceutical Analysis. Pharm Anal Acta. 13:680